Morphine

Front 1

MORPHINE
Class/MOA

Back 1

Class
Opioid analgesic. (Schedule II drug).
Mechanism of Action
Alleviates pain through CNS actions
Suppresses fear and anxiety centers in brain.
Depresses brain stem respiratory centers.
Increases peripheral venous capacitance and decreases venous return.
Decreases preload and afterload, decreasing myocardial oxygen demand.

Front 2

MORPHINE
I/CI

Back 2

Indications
Analgesia for moderate to severe acute and chronic pain (use with caution).
Severe CHF, pulmonary edema.
Chest pain associated with acute MI.
Contraindications
Head injury, exacerbated COPD, depressed respiratory drive, hypotension.
Undiagnosed abdominal pain, decreased level of consciousness.
Suspected hypovolemia.
Patients who have taken MAOIs within past 14 days.

Front 3

MORPHINE
AR/DI

Back 3

Adverse Reactions
Respiratory depression, hypotension, decreased level of consciousness, nausea,
vomiting.
Bradycardia, tachycardia, syncope, facial flushing, euphoria, bronchospasm, dry mouth.
Drug Interactions
Potentates sedative effects of phenothiaxines.
CNS depressant may potentate effects of morphine.
MAOIs may cause paradoxical excitation.

Front 4

MORPHINE
How Supplied

Back 4

How Supplied
10 mg in 1 ml of solution, ampules and Tubex syringes.

Front 5

MORPHINE
Dosages

Back 5

Dosage and Administration
Adult: 1-3 mg IV, IM, SC every 5 minutes titrated to maximum of 10 mg.
Adult: Morphine 0.1mg/kg to a maximum of 10mg IV/IM/SC
~
Pediatric: 0.1 - 0.2 mg / kg / dose IV, IO, IM, SC every 5 minutes titrated to max. of
5 mg.

Front 6

MORPHINE
DOA/specials

Back 6

Duration of Action
Onset: Immediate.
Peak effect: 20 minutes.
Duration: 2 - 7 hours.
Special Considerations
Pregnancy safety: Category C.
Morphine rapidly crosses the placenta.
Safety in neonate not established.
Use with caution in geriatric population and those with COPD, asthma.
Vagotonic effect in patient with acute inferior MI (bradycardia, heart block).
Naloxone should be readily available as antidote.